Antibody titration is used to determine the concentration of a specific antibody and it is a critical factor in various clinical settings. However, antibody titration is generally known as an inherently imprecise procedure. So, automating the procedure is an important step towards better standardization, higher accuracy, and full traceability.
Prophylactic anti-D has been introduced to prevent the occurrence of anti-D alloimmunization during pregnancy and has been shown to be very effective. During antibody screening, the development of weak immune anti-D is indistinguishable from passive anti-D as a result of prophylactic anti-D. However, it is very important to ensure correct interpretation as this may have major clinical implications.
In this webinar, Dr. Cécile TOLY-NDOUR PharmD, PhD will tell us how the automated anti-D microtitration on the IH-500 system can easily distinguish passive from immune anti-D. She will also share how the use of the automated gel anti-D titration method on the IH-500 system is beneficial, its correlation to the reference tube method, and the added value of the gel titer score for monitoring pregnancies complicated by an anti-D alloimmunization.
Dr. Cécile TOLY-NDOUR, PharmD, PhD,
has been a hospital practitioner, since 2012 at the laboratory of the French National Reference Center in Perinatal Hemobiology, St Antoine Hospital, (Assistance Publique des hôpitaux de Paris), Paris, France.
Dr. Cécile TOLY-NDOUR, PharmD, PhD in Immunology, has been a hospital practitioner since 2012 at the laboratory of the French National Reference Center in Perinatal Hemobiology, Saint Antoine Hospital, (Assistance Publique des hôpitaux de Paris) in Paris (headed by Dr Agnès MAILLOUX). The center is comprised of biological and clinical entities and performs the follow-up of pregnancies complicated by red blood cell (RBC) and platelet alloimmunization and manages fetuses and newborns suffering from severe hemolytic disease. Other specialties of the center are feto-maternal hemorrhage diagnosis and management as well as Rh disease prevention. Besides these medical activities, Cécile TOLY-NDOUR is also participating in the development of new biological assays in the field of maternal, fetal, or neonatal hemobiology. She is also involved in different epidemiological studies about maternal immunization and fetal/neonatal hemolytic disease and in education units on immunohematology or perinatal hemobiology. She is also co-chairing a working group within the French Society for Blood Transfusion about fetomaternal red blood cell immunization and is part of the ISBT “Immunohematology” Working Party. She has authored over 20 publications in various journals and has given over 15 oral communications at international and national congresses.